Today the company said it expects to return to revenue growth in 2025 when the ongoing decline in its COVID-19 vaccine business would bottom out, and that it would invest to scale up its oncology business thereafter.
Tag Archive for: MRNA technology
The experimental personalized mRNA cancer treatment is used in combination with blockbuster drug Keytruda for patients with a type of lung cancer.
Looking beyond the coronavirus business, the company has renewed its focus on a growing development pipeline in oncology, which includes use of the mRNA technology pioneered in the vaccine as well as precision anti-cancer drugs from a class known as antibody-drug conjugates and therapies based on modified immune cells.
While medicines consisting of modified RNA have been decades in the making, it took the pressure of a global pandemic to push the promising technology past hurdles and onto the market. Thanks to a great deal of innovation, mRNA is now a household name and a rapidly expanding industry for the biopharma world beyond COVID-19. Over 250 potential mRNA therapies are currently being investigated in cancer, with more than 500 in other indications.
CEPI will provide funding of up to $90 million to support the development of vaccine candidates which is based on BioNTech’s mRNA technology.
During Wednesday’s annual R&D Day, Moderna said it is culling four programs from its pipeline, including two molecules that had been discontinued last year by AstraZeneca.
Moderna said the companies would use Immatics’ drug discovery platform to develop mRNA-based cancer vaccines, and also study its own cancer vaccine for use in combination with Immatics’ cancer therapy IMA203.
Promosome filed lawsuits Tuesday against Moderna and Pfizer/BioNTech, alleging that the vaccine developers used patent-protected mRNA technology without a license.
Adding an experimental mRNA-based vaccine from Moderna and Merck reduced the risk that the most deadly skin cancer would spread by 65% over treatment with an immunotherapy alone in a midstage trial, the companies reported today.
The company said it filed a counterclaim alleging that Pfizer and its German partner BioNTech infringed on nine of its patents, broader than its original claim of three patents.
